2026-10-25
Does not pass
Nebius does not pass the ethical screen. The binding factor is interest/revenue 6.0%.
NAS100 28,385 −3.46%
S&P 7,580 −1.82%
GOLD $3,899 −3.29%
BTC $77,765 +0.73%
VIX 19.42 +12.91%
latest tape · as of 06:01 UTC
The Screen · Communication Services · Internet Content & Information
Nebius Group N.V.
NBIS · Nasdaq · USD · Market cap $43.7B · 1,543 employees
Nebius Group N.V., a technology company, engages in building full-stack infrastructure to service the global AI industry in the United States, the United Kingdom, and internationally.
FAIL · Does not pass the screen154.14 USD
Price as of 30 Oct 2026Daily close, not a live quote
Screened 2026-10-30 · the tape above runs as of 06:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price154.14 USD at the 30 Oct 2026 close
- Our ratingAvoid, current read markdown
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.28)
- Last reviewed30 Oct 2026 (2 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 154.14 against the desk's fair-value range, base estimate 302.00, over the last year.
- Trend Markdown
- Insiders insiders bought, latest filing 2026-10-29
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.28, read 2026-10-30
- Ethical does not pass the values gate
Price154.14 USD
Fair value302.00
Ethical score93.7/100
RatingAVOID
Our investment reviews on this name
2026-10-11Read Markdown237.33-35.1% to today ✓Accumulation gives way to Markdown
2026-10-02Read Accumulation237.33-35.1% to today Markup gives way to Accumulation
2026-07-02Read Markup227.81-32.3% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markdown label.
Nebius Group N.V. holds its Markdown at $154.14. Consolidating, no directional conviction, held for 31 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 31 days |
| Price at the screen | $154.14 |
| Valuation | 134.37 trailing · -47.80 forward price to earnings |
| Values screen | FAIL · score 93.7 |
| Beta | 1.46 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 6.0%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 9.45% | Below 33% | Interest-bearing debt is just 9.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 7.13% | Below 33% | Cash held in interest-bearing accounts and securities is 7.1% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 6.00% | Below 5% | 6.0% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Nebius does not pass the ethical screen. The binding factor is interest/revenue 6.0%.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Nebius clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 9%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when NBIS's ethical verdict changes
Today NBIS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads AVOID: it trades at roughly a 96% discount to our $302.00 fair value, 454.00% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. A 95.9% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus Buy. The average target sits +96% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsAI infrastructure race meets stretched valuations
Picture the scramble to lay down the power-hungry GPU farms that will train tomorrow's models. Nebius is one of the smaller players racing to supply that full-stack capacity across the US, Europe and beyond.
Revenue jumped 684% last year with a 93% profit margin and 14% ROE. Those are headline numbers, yet the shares trade at 492 times forward earnings and sit 26% above our fair value of $131.47. The market is already paying for perfection.
Execution risk in a crowded field is high, and any slowdown in AI spend would hit the multiple hard. Analysts still see room to $255, but the gap to our number leaves little margin for slips. Ethical screen passed.
Analysis, not advice.
| Forward P/E | -47.8x |
| Trailing P/E | 134.4xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 1.28 |
| EPS, forward | -3.60 |
| Revenue growth | +454.0%growing very fast |
| Profit margin | 3.1%barely profitable |
| Return on equity | 0.6%a modest return on shareholder capital |
| FCF yield | -22.02% |
| Debt to equity | 0.99moderate, manageable leverage |
| Current ratio | 4.03comfortably covers its short-term bills |
| Beta | 1.46moves a little more than the market |
| Short interest, float | 0.20% |
| 52-week range | 73.52 - 299.86 |
| Market cap | $43.7B |
| Employees | 1,543 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Netherlands and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeNBIS trades on Nasdaq (the company is based in Netherlands). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-25
Markdown $188.41
+0.0% Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
2026-10-18
Markdown $188.41
-20.6% Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 20.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
2026-10-11
Markdown · changed $237.33
+0.0% Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
2026-10-02
Accumulation · changed $237.33
+7.8% Entry 6
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231. Since the last review it entered the Tech 100.
2026-09-06
Markup $220.11
+0.5% Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
2026-08-06
Markup $218.99
-3.9% Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
2026-07-18
Markup $227.81
+0.0% Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
2026-07-03
Markup $227.81
+0.0% Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02
Markup $227.81
Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Nebius Group (NBIS) Starts On Site Power At Its 300 MW New Jersey Data Center Yahoo Finance · 7d ago
- 5 Oversold AI Stocks: Where Wall Street Analysts Are Spotting 50%+ Upside Yahoo Finance · 7d ago
- 5 of the Fastest-Growing Stocks in the Market Yahoo Finance · 8d ago
- Anthropic IPO Watch, SpaceX’s Soaring Compute Pricing, Wall Street’s Takes on CoreWeave vs. Nebius Yahoo Finance · 8d ago
- These 2 Neocloud Stocks Could Rebound Over 90%, Say Analysts Yahoo Finance · 9d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
RDDTReddit Inc
SPOTSpotify Technology SA
TMETencent Music Entertainment Group ADR
PINSPinterest Inc
MTCHMatch Group, Inc.
SNAPSnap Inc
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-29 | Grimme Arne | Dir | P - Purchase | 148 | $25,074 |
| 2026-10-27 | Grimme Arne | Dir | P - Purchase | 353 | $57,740 |
| 2026-10-22 | Grimme Arne | Dir | P - Purchase | 770 | $122,438 |
| 2026-10-19 | Grimme Arne | Dir | P - Purchase | 148 | $25,159 |
| 2026-10-15 | Grimme Arne | Dir | P - Purchase | 296 | $50,317 |
| 2026-10-12 | Boroditsky Marc | Chief Revenue Officer | S - Sale+OE | 7,000 | $1,478,610 |
| 2026-10-05 | Nave Ophir | COO | S - Sale | 500,000 | $117,765,468 |
| 2026-10-01 | Korolenko Andrey | Chief Infrastructure Officer | S - Sale | 29,090 | $6,811,714 |
| 2026-10-01 | Shtan Danila | CTO | S - Sale | 14,546 | $3,406,091 |
| 2026-10-01 | Volozh Arkadiy | CEO, 10% | S - Sale | 37,778 | $8,846,096 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $186.10 | +14.1% | · | $1,141 | +14.1% |
| 2 months | $144.97 | +46.5% | · | $1,465 | +46.5% |
| 3 months | $108.04 | +96.6% | · | $1,966 | +96.6% |
| 6 months | $94.28 | +125.3% | · | $2,253 | +125.3% |
| 1 year | $52.51 | +304.5% | · | $4,045 | +304.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NBIS does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.